Skip Navigation

Link to the National Institutes of Health NIDA NEWS NIDA News RSS Feed
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Keep Your Body Healthy
Go to the Home pageGo to the About Nida pageGo to the News pageGo to the Meetings & Events pageGo to the Funding pageGo to the Publications page
PhysiciansResearchersParents/TeachersStudents/Young AdultsEn Español Drugs of Abuse & Related Topics
National Institute on Drug Abuse Clinical Trials Network
   
Short-Term Opioid Withdrawal Using Buprenorphine

The primary goal of these products is to instruct treatment providers about a unique, 13-day buprenorphine intervention for opioid dependent patients. The CTN protocol compared this 13-day buprenorphine taper intervention to a standard treatment (clonidine detoxification) in both inpatient and outpatient settings. More patients who received buprenorphine were able to provide an opioid negative urine sample upon completion of the intervention when compared to the standard treatment group.

Products:

Projected completion: Spring 2006

Blending Team Members:
NIDA:
Scott Kellogg, Ph.D.
 Nancy Petry, Ph.D.
Therese Killeen, Ph.D.
John Hamilton, MFT
CSAT/ATTC:
Lonnetta Albright (Lead)
Anne Helene Skinstad, Ph.D.
Amy Shanahan, M.S.
Joe Rosenfeld, Ph.D.
Back to
main Blending
Team page

NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version

National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Monday, May 15, 2006. The U.S. government's official web portal